{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "f5ddf433",
   "metadata": {},
   "outputs": [],
   "source": [
    "from qdrant_client import QdrantClient\n",
    "from qdrant_client.models import VectorParams, PointStruct\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "# Connect to local Qdrant container\n",
    "client = QdrantClient(host=\"localhost\", port=6333)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0604243c",
   "metadata": {},
   "source": [
    "Prepare the dataset."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "d6ebeab9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add parent directory to sys.path\n",
    "import sys\n",
    "import os\n",
    "import importlib\n",
    "import pdf_to_clean_text\n",
    "\n",
    "# Get current notebook directory\n",
    "notebook_dir = os.getcwd()\n",
    "parent_dir = os.path.abspath(os.path.join(notebook_dir, '..'))\n",
    "sys.path.append(parent_dir)\n",
    "\n",
    "importlib.reload(pdf_to_clean_text)\n",
    "\n",
    "from pdf_to_clean_text import clean_text, read_pdf2\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "135a2784",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/home/non-sudo/CSE-291-RAG-Project-UCSD/notebooks/../dataset\n",
      "['TP53_effects_breast_cancer', 'pq2402015632.pdf']\n"
     ]
    }
   ],
   "source": [
    "# Load the dataset.\n",
    "dataset_dir = os.path.join(os.getcwd(), \"..\", \"dataset\")\n",
    "print(dataset_dir)\n",
    "print(os.listdir(dataset_dir))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "fba4a41d",
   "metadata": {},
   "outputs": [],
   "source": [
    "breast_cancer_dir = os.path.join(dataset_dir, \"TP53_effects_breast_cancer\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "b0987610",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Contents lists available at ScienceDirect \n",
      "\n",
      "Cancer Treatment Reviews \n",
      "\n",
      "journal homepage: www.elsevier.com/locate/ctrv \n",
      "\n",
      "Tumour Review \n",
      "\n",
      "Germline TP53 pathogenic variants and breast cancer: A narrative review \n",
      "\n",
      "Eva Blondeaux a,*, Luca Arecco b,c, Kevin Punie d, Rossella Graffeo e, Angela Toss f, \n",
      "Carmine De Angelis g, Lucia Trevisan h, Giulia Buzzatti h, Sabine C. Linn i, Peter Dubsky j, \n",
      "Mara Cruellas k, Ann H. Partridge l, Judith Balma˜na k, Shani Paluch-Shimon m, \n",
      "Matteo Lambertini b,c \n",
      "a Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy \n",
      "b Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy \n",
      "c Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy \n",
      "d Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium \n",
      "e Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland \n",
      "f Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy \n",
      "g Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy \n",
      "h Hereditary Cancer Unit, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy \n",
      "i Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands \n",
      "j Breast Centre, Hirslanden Klinik St Anna, Luzern, Switzerland \n",
      "k Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain \n",
      "l Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA \n",
      "m Breast Cancer Unit, Sharett Institute of Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University, 91120 Jerusalem, Israel \n",
      "\n",
      "Keywords: \n",
      "Breast cancer \n",
      "TP53 \n",
      "Prognosis \n",
      "Treatment \n",
      "\n",
      "Approximately 10% of breast cancers are associated with the inheritance of a pathogenic variant (PV) in one of \n",
      "the breast cancer susceptibility genes. Multiple breast cancer predisposing genes, including TP53, are responsible \n",
      "for the increased breast cancer risk. \n",
      "\n",
      "Tumor protein-53 (TP53) germline PVs are associated with Li-Fraumeni syndrome, a rare autosomal dominant \n",
      "such as soft tissue and bone sarcomas, breast cancer, brain tumors, adrenocortical carcinomas and leukemias. \n",
      "Women harboring a TP53 PV carry a lifetime risk of developing breast cancer of 80–90%. \n",
      "\n",
      "The aim of the present narrative review is to provide a comprehensive overview of the criteria for offering \n",
      "prognostic and therapeutic implications. A summary of the current indications of secondary cancer surveillance \n",
      "and survivorship issues are also provided. Finally, the spectrum of TP53 alteration and testing is discussed. \n",
      "\n",
      "The optimal strategies for the treatment of breast cancer in patients harboring TP53 PVs poses certain chal-\n",
      "lenges. Current guidelines favor the option of performing mastectomy rather than lumpectomy to avoid adjuvant \n",
      "radiotherapy and subsequent risk of radiation-induced second primary malignancies, with careful consideration \n",
      "of radiation when indicated post-mastectomy. Some studies suggest that patients with breast cancer and germline \n",
      "TP53 PV might have worse survival outcomes compared to patients with breast cancer and wild type germline \n",
      "TP53 status. Annual breast magnetic resonance imaging (MRI) and whole-body MRI are recommended as sec-\n",
      "ondary prevention. \n",
      "\n",
      "Introduction \n",
      "\n",
      "Breast cancer is the most common cancer diagnosis in women and \n",
      "the majority are considered sporadic cases . Around 10% of breast \n",
      "\n",
      "malignancies are associated with a germline pathogenic variant in one of \n",
      "\n",
      "* Corresponding author at: IRCCS Ospedale Policlinico San Martino, Clinical Epidemiology Unit, Largo Rosanna Benzi 10, 16132 Genova, Italy. \n",
      "\n",
      "E-mail address: evablondeaux@gmail.com (E. Blondeaux). \n",
      "\n",
      "https://doi.org/10.1016/j.ctrv.2023.102522 \n",
      "Received 5 December 2022; Received in revised form 24 January 2023; Accepted 26 January 2023 \n",
      "\n",
      "CancerTreatmentReviews114(2023)102522Availableonline31January20230305-7372/©2023TheAuthors.PublishedbyElsevierLtd.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).\fE. Blondeaux et al. \n",
      "\n",
      "variants involved in increased breast cancer risk and pathogenic variants \n",
      "in multiple other breast cancer predisposing genes, including TP53, are \n",
      "responsible for the remaining [4–6]. \n",
      "\n",
      "Tumor protein-53 (TP53) gene is a tumor suppressor which controls \n",
      "resulting from DNA damage by suppressing proliferation or activating \n",
      "autosomal dominant inherited cancer predisposition syndrome histori-\n",
      "cally associated with early-onset pediatric and multiple primary cancers \n",
      "adrenocortical carcinomas, gastrointestinal, lung, pancreatic and pros-\n",
      "variants were associated also with an increased risk of prostate cancer \n",
      ". The cumulative cancer risk associated with Li-Fraumeni syndrome \n",
      "has been estimated to be approximately 50% by the age of 40 years and \n",
      "up to 90% by the age of 60 years with females reported to have a \n",
      "pausal breast cancer [15–17]. Indeed, healthy women harboring a TP53 \n",
      "pathogenic variant carry a lifetime risks of developing breast cancer of \n",
      "around 80–90%, higher than the risk of healthy BRCA carriers (lifetime \n",
      "risk of around 60–85%) [18–21]. \n",
      "\n",
      "The aim of the present narrative review is to give a comprehensive \n",
      "overview of all the aspects to be considered during the counselling of \n",
      "women with a new diagnosis of breast cancer and carrying (or suspected \n",
      "to carry) a TP53 pathogenic variant. Criteria for offering TP53 testing, \n",
      "nostic and therapeutic implications are provided. Current indications of \n",
      "Finally, the spectrum of TP53 alteration and testing is discussed. \n",
      "\n",
      "Criteria for offering TP53 testing and prevalence of TP53 carriers \n",
      "among patients with breast cancer \n",
      "\n",
      "(Table 1). \n",
      "\n",
      "criteria were proposed in order to expand the proband’s cancer types \n",
      "to include childhood cancers, brain cancers, and adrenal cortical carci-\n",
      "noma, and to change the relatives’ age at the time of diagnosis to < 60 \n",
      "leagues in 2001 and a modified version of the Chompret criteria was \n",
      "proposed by Bougeard and colleagues in 2015 with the recommendation \n",
      "to offer TP53 testing to patients with breast cancer diagnosis before age \n",
      "these criteria have been estimated to be around 90% and 50% respec-\n",
      "families who do not fulfill these clinical criteria due to a wide variety of \n",
      "phenotypes within the same syndrome, different tumor spectrum, age at \n",
      "positive family history does not exclude the possibility of the identifi-\n",
      "cation of a TP53 pathogenic variant in the patient . \n",
      "\n",
      "In 2020, the European Reference Network GENTURIS expanded the \n",
      "lymphoblastic leukemia, medulloblastoma or jaw osteosarcoma, as well \n",
      "Brazilian families and patients affected by second primary malignancy \n",
      "considered eligible for TP53 testing . Despite the available evidence \n",
      "regarding the higher prevalence of human epidermal growth factor re-\n",
      "ceptor 2 (HER2) positive breast cancer among TP53 carriers , none \n",
      "of the above-mentioned criteria consider histopathological features of \n",
      "\n",
      "Table 1 \n",
      "Criteria for offering TP53 testing. \n",
      "\n",
      "Criteria \n",
      "\n",
      "Year \n",
      "\n",
      "General criteria \n",
      "\n",
      "Classic Li–Fraumeni \n",
      "\n",
      "criteria \n",
      "\n",
      "Birch criteria (LFL) \n",
      "\n",
      "Eeles criteria (LFL) \n",
      "\n",
      "Chompret criteria \n",
      "\n",
      "Modified Chompret \n",
      "\n",
      "criteria \n",
      "\n",
      "GENTURIS criteria* \n",
      "\n",
      "Proband with sarcoma diagnosed before 45 years \n",
      "\n",
      "First-degree relative with any cancer before 45 \n",
      "years \n",
      "\n",
      "First or second-degree relative with any cancer \n",
      "before 45 years or a sarcoma at any age \n",
      "Proband with any childhood cancer, or a sarcoma, \n",
      "or a brain tumor or ACC before 45 years \n",
      "\n",
      "First or second-degree relative with a core LFS \n",
      "cancer (sarcoma, breast cancer, brain tumor, ACC \n",
      "or leukemia) at any age \n",
      "\n",
      "First or second-degree relative with any cancer \n",
      "before 60 years \n",
      "Two first- or second-degree relatives with core LFS \n",
      "malignancies (sarcoma, premenopausal breast \n",
      "cancer, brain tumor ACC, leukemia, lung \n",
      "[bronchoalveolar] cancer) at any age \n",
      "Proband affected by a narrow spectrum cancer (i. \n",
      "e., sarcomas, brain tumors, breast cancer, and \n",
      "ACC) before 36 years and at least one first or \n",
      "second-degree relative affected by a narrow \n",
      "spectrum tumor (other than breast cancer if the \n",
      "proband is affected by breast cancer) before 46 \n",
      "years or multiple primary tumors \n",
      "\n",
      "Proband with multiple primary tumors; two of \n",
      "which belong to the narrow spectrum with the first \n",
      "of which occurred before 36 years \n",
      "\n",
      "Proband with ACC \n",
      "Proband with tumor belonging to LFS tumor \n",
      "spectrum (e.g., soft tissue sarcoma, osteosarcoma, \n",
      "brain tumor, breast cancer, ACC, leukemia, \n",
      "bronchoalveolar lung cancer) before 46 years and \n",
      "at least one first- or second-degree relative with an \n",
      "above LFS tumor (except breast cancer if proband \n",
      "has breast cancer) before 56 years or with multiple \n",
      "tumors at any age \n",
      "\n",
      "Proband with multiple tumors (except multiple \n",
      "breast tumors), two of which belong to LFS tumor \n",
      "spectrum and the first occurring before 46 years \n",
      "\n",
      "Patient with ACC, choroid plexus carcinoma, or \n",
      "rhabdomyosarcoma of embryonal anaplastic \n",
      "subtype, irrespective of family history \n",
      "\n",
      "Breast cancer before age 31 years \n",
      "Patient with a TP53 core tumor (breast cancer, \n",
      "soft-tissue sarcoma, osteosarcoma, central nervous \n",
      "system tumor, ACC) before 46 years and at least \n",
      "one first- or second-degree relative with a core \n",
      "tumor before 56 years \n",
      "\n",
      "Patient with multiple tumors, including two TP53 \n",
      "core tumors, the first of which occurred before 46 \n",
      "years, irrespective of family history \n",
      "\n",
      "Patient with ACC, choroid plexus carcinoma, or \n",
      "rhabdomyosarcoma of embryonal anaplastic \n",
      "subtype, irrespective of family history \n",
      "\n",
      "Breast cancer before age 31 years \n",
      "\n",
      "Children and adolescents with hypodiploid ALL or \n",
      "otherwise unexplained sonic hedgehog-driven \n",
      "medulloblastoma or jaw osteosarcoma \n",
      "\n",
      "Patients who develop a second primary tumor, \n",
      "within the radiotherapy field of a first core TP53 \n",
      "tumor which occurred before 46 years \n",
      "\n",
      "(continued on next page) \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025222\fE. Blondeaux et al. \n",
      "\n",
      "Table 1 (continued ) \n",
      "\n",
      "Criteria \n",
      "\n",
      "Year \n",
      "\n",
      "General criteria \n",
      "\n",
      "Evans criteria* \n",
      "\n",
      "Children with any cancer from southern and \n",
      "south-eastern Brazilian families a \n",
      "Invasive breast carcinoma or DCIS before 31 years \n",
      "\n",
      "Bilateral invasive breast carcinoma or DCIS or \n",
      "multifocal invasive breast carcinoma or HER2 +\n",
      "invasive breast carcinoma or phyllode tumor \n",
      "before 36 years \n",
      "\n",
      "Invasive breast carcinoma and a second TP53 core \n",
      "tumor in the patient before 46 years \n",
      "\n",
      "Invasive breast carcinoma before 46 years and one \n",
      "first- or second-degree relative with a TP53 core \n",
      "tumor before 56 years \n",
      "\n",
      "LFL, Li–Fraumeni-like; ALL, acute lymphoblastic leukemia; DCIS, ductal carci-\n",
      "noma in situ; HER2, human epidermal growth factor receptor 2. \n",
      "\n",
      "* Breast cancer-specific testing criteria, not formally tested for sensitivity and \n",
      "\n",
      "specificity. \n",
      "\n",
      "a To be tested for the p.R337H Brazilian founder germline TP53 variant. \n",
      "\n",
      "Evans and colleagues, different age thresholds are proposed for patients \n",
      "with HER2 positive breast cancer or phyllode tumor . \n",
      "\n",
      "evaluating the prevalence of TP53 germline carriers in selected patients \n",
      "with breast cancer (Table 2). \n",
      "\n",
      "germline pathogenic variant, including women with breast cancer who \n",
      "cancer risk related to different breast cancer susceptibility genes, TP53 \n",
      "pathogenic variant were identified in 19 (0.06%) out of 32,247 unse-\n",
      "Cancer Association Consortium) [5,6]. \n",
      "\n",
      "In a cohort of 364 female patients from the Netherlands diagnosed \n",
      "with breast cancer before the age of 30 years, 8 (2.2%) patients harbored \n",
      "a (likely) pathogenic TP53 variant . Among them, 6 patients had a \n",
      "personal or familial history suggestive of Li-Fraumeni syndrome . In \n",
      "an Australian population-based cohort of invasive breast cancers, TP53 \n",
      "(likely) pathogenic variants were detected in 2 (4%) out of 52 women \n",
      "diagnosed before age of 30 unselected for family history and in 3 (7%) \n",
      "second-degree relatives with breast or ovarian cancer . In a cohort of \n",
      "Polish females with breast cancer diagnosed before the age of 30 \n",
      "years and positive family history of cancer, prevalence of TP53 patho-\n",
      "genic variant was 4% . \n",
      "\n",
      "To note that the identification of a pathogenic variant can be influ-\n",
      "quencies of TP53 germline carriers should be interpreted with caution. \n",
      "broader diagnostic criteria and more inclusive testing criteria will lead \n",
      "to a considerably higher prevalence of germline TP53 pathogenic vari-\n",
      "\n",
      "Table 2 \n",
      "Studies exploring TP53 germline pathogenic variant prevalence among selected patients with breast cancer. \n",
      "\n",
      "Author \n",
      "\n",
      "Year \n",
      "\n",
      "Selection criteria \n",
      "\n",
      "No. of pts \n",
      "tested \n",
      "\n",
      "BRCA1/2 \n",
      "status \n",
      "\n",
      "TP53 (likely) pathogenic \n",
      "variant prevalence (%) \n",
      "\n",
      "Evans DGR et al \n",
      "\n",
      "Walsh T et al \n",
      "\n",
      "Probands with sarcoma and BC (BC in proband or in a first degree \n",
      "relative) in family not fulfilling LFS \n",
      "Probands from families with 4 or more cases of BC or ovarian cancer \n",
      "\n",
      "Lalloo F et al \n",
      "\n",
      "BC ≤ 30 years \n",
      "\n",
      "Manoukian S et al \n",
      "\n",
      "Ginsburg OM et al \n",
      "\n",
      "Gonzalez KD et al \n",
      "Mouchawar Jet al \n",
      "\n",
      "Lee DSC et al \n",
      "McCuaig JM et al \n",
      "Rath MG et al \n",
      "Carraro DM et al \n",
      "Bougeard G et al \n",
      "Eccles DM et al \n",
      "Hahn EC et al \n",
      "\n",
      "Unrelated individuals from families with one case of sarcoma and at least \n",
      "one case of BC \n",
      "BC < 30 years \n",
      "\n",
      "BC between 30 and 49 years \n",
      "(a) women diagnosed with BC before the age of 30 years irrespective of \n",
      "family history \n",
      "(b) women diagnosed with BC between 30 and 39 years with two or more \n",
      "first- or second-degree relatives with BC or ovarian cancer \n",
      "BC < 37 years \n",
      "BC < 30 years \n",
      "HER2-positive BC, <51 years \n",
      "BC < 35 years \n",
      "BC < 31 years \n",
      "HER2-positve BC, <31 years \n",
      "\n",
      "Women with BC diagnosed before 46 years and without Chompret \n",
      "\n",
      "Bakhuizen JJ et al \n",
      "\n",
      "criteria for LFS or LFL \n",
      "BC < 30 years \n",
      "\n",
      "Gallardo-Alvarado LN \n",
      "\n",
      "BC < 45 years \n",
      "\n",
      "et al \n",
      "\n",
      "Rogo˙za-Janiszewska E \n",
      "\n",
      "BC ≤ 30 years \n",
      "\n",
      "et al \n",
      "\n",
      "Siraj AK et al \n",
      "\n",
      "BC ≤ 40 years \n",
      "\n",
      "Waks AG et al \n",
      "\n",
      "BC ≤ 35 years \n",
      "\n",
      "Negative \n",
      "\n",
      "4.8% (1/21) \n",
      "\n",
      "12% BRCA1/2 \n",
      "mutated \n",
      "18% BRCA1/2 \n",
      "mutated \n",
      "Negative \n",
      "\n",
      "1% (3/300) \n",
      "\n",
      "4% (4/100) \n",
      "\n",
      "13% (3/23) \n",
      "\n",
      "Negative \n",
      "\n",
      "0% (0/95) \n",
      "\n",
      "(a) 52 \n",
      "\n",
      "Negative \n",
      "Negative \n",
      "\n",
      "7.1% (1/14) \n",
      "(a) 4% (2/52) \n",
      "\n",
      "(b) 42 \n",
      "\n",
      "Negative \n",
      "\n",
      "(b) 7% (3/42) \n",
      "\n",
      "Negative \n",
      "Negative \n",
      "Negative \n",
      "Negative \n",
      "\n",
      "Negative \n",
      "Negative \n",
      "\n",
      "19/364 \n",
      "BRCA1/2 \n",
      "mutated \n",
      "Negative \n",
      "\n",
      "4.8% (4/83) \n",
      "21.4% (6/28) \n",
      "1.4% (3/213) \n",
      "2.3% (1/43) \n",
      "6% (NR) \n",
      "8.5% (5/71) \n",
      "2.5% (6/239) \n",
      "\n",
      "2.2% (8/364) \n",
      "\n",
      "6.4% (5/78) \n",
      "\n",
      "Negative \n",
      "\n",
      "4% (4/100) \n",
      "\n",
      "57/464 BRCA1/ \n",
      "mutated \n",
      "13/92 BRCA1/2 \n",
      "mutated \n",
      "\n",
      "1.5% (7/464) \n",
      "\n",
      "1.1% (1/92) \n",
      "\n",
      "Abbreviations: BC, breast cancer; FH, familial history; LFS, Li-Fraumeni syndrome; LFL, Li-Fraumeni-Like syndrome; NR, not reported. \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025223\fE. Blondeaux et al. \n",
      "\n",
      "syndrome [19,37]. In fact, multigene panel studies gave the possibility \n",
      "[12,54,55]. \n",
      "\n",
      "Breast cancer subtypes arising in TP53 carriers \n",
      "\n",
      "breast cancer subtypes. Some previous reports suggested that patients \n",
      "harboring germline TP53 pathogenic variants are more likely to develop \n",
      "HER2-positive breast cancers (Table 3). \n",
      "\n",
      "In particular, a multicenter international case-control analysis of the \n",
      "BRIDGES study including 42,680 patients and 46,387 controls aimed to \n",
      "characterize tumors associated with different breast cancer susceptibil-\n",
      "ity genes . Among the 42,680 patients included, 51 harbored a TP53 \n",
      "pathogenic variant. TP53 carriers were found to have a greater chance to \n",
      "develop HER2-positive breast cancers (46% of cases) . Moreover, \n",
      "TP53 carriers were more likely to have mixed lobular and ductal tumors \n",
      "than ductal carcinoma (OR 7.01, 95% CI 3.04–16.17) . In a Brazilian \n",
      "cohort of 91 TP53 female carriers, breast cancer was the first malignancy \n",
      "diagnosed in 90% of the women, of whom 78% had an early-onset breast \n",
      "cancer (i.e. age ≤ 45 years) . Moreover, bilateral breast cancer was \n",
      "observed in 29% of the patients. Overall, 41% of the tumors were HER2- \n",
      "positive, and 33% were positive for both hormone receptor and HER2 \n",
      ". \n",
      "\n",
      "Many other studies with<50 patients provided similar results with a \n",
      "prevalence of HER2 positivity ranging between 34 and 83% (Table 3) \n",
      "[33,56–63], clearly higher than expected in an unselected breast cancer \n",
      "population (15–20%) [65,66]. \n",
      "\n",
      "Breast cancer prognosis \n",
      "\n",
      "Several studies evaluated survival outcomes of patients with breast \n",
      "\n",
      "Table 3 \n",
      "Tumor subtypes among TP53 carriers. \n",
      "\n",
      "Author \n",
      "\n",
      "Year \n",
      "\n",
      "TP53 \n",
      "carriers \n",
      "with BC \n",
      "\n",
      "HER2 \n",
      "positive \n",
      "tumors \n",
      "\n",
      "Wilson JRF et al \n",
      "\n",
      "12* \n",
      "\n",
      "10* (83%) \n",
      "\n",
      "Melhem-Bertrandt A \n",
      "\n",
      "(67%) \n",
      "\n",
      "et al \n",
      "\n",
      "Masciari S et al \n",
      "Bakhuizen JJ et al \n",
      "\n",
      "32* \n",
      "(63%) \n",
      "(63%) \n",
      "\n",
      "Packwood K et al \n",
      "\n",
      "(56%) \n",
      "\n",
      "Le A et al \n",
      "Alyami H et al \n",
      "\n",
      "38* \n",
      "21* \n",
      "\n",
      "(58%) \n",
      "(53%) \n",
      "\n",
      "Kuba MG et al \n",
      "\n",
      "(53%) \n",
      "\n",
      "Rippinger N et al \n",
      "\n",
      "(34%) \n",
      "\n",
      "NR (46%) \n",
      "\n",
      "Breast Cancer \n",
      "Association \n",
      "Consortium, \n",
      "Mavaddat N et al \n",
      "\n",
      "Sandoval RL et al \n",
      "\n",
      "(41%) \n",
      "\n",
      "– \n",
      "\n",
      "– \n",
      "\n",
      "– \n",
      "– \n",
      "\n",
      "– \n",
      "\n",
      "– \n",
      "\n",
      "cases of malignant \n",
      "phyllodes tumor \n",
      "cases of HER2 \n",
      "negative BC by IHC \n",
      "(1 + ) but positive \n",
      "by FISH. \n",
      "cases (31.3%) of \n",
      "luminal B-like BC \n",
      "OR for HER2 + BC \n",
      "(95%CI \n",
      "3.34–15.28) \n",
      "\n",
      "cases (55%) of \n",
      "luminal-like BC \n",
      "\n",
      "BC, breast cancer. \n",
      "\n",
      "* invasive breast cancers. \n",
      "\n",
      "cancer according to somatic TP53 pathogenic variants [67–70]. How-\n",
      "ever, few data are available regarding clinical outcomes of patients with \n",
      "breast cancer according to germline TP53 mutation status. In a cohort of \n",
      "10,053 unselected Chinese patients with early-stage breast cancer, the \n",
      "patients with a germline TP53 pathogenic variant had significantly \n",
      "worse relapse-free survival (adjusted HR = 2.24; 95%CI 1.15–4.33; p =\n",
      "1.41–5.30; p = 0.003) and overall survival (adjusted HR = 4.60; 95%CI, \n",
      "2.26–9.41; p < 0.001) as compared to patients with early stage breast \n",
      "breast cancer and a second cohort of 1820 patients with breast cancer \n",
      "strated that the rate of ipsilateral breast tumor recurrence after breast \n",
      "conserving surgery was significantly higher in TP53 carriers than in non- \n",
      "carriers (21.1% vs 3.8%) . Moreover, the 10-year risk of contralat-\n",
      "eral breast cancer in TP53 carriers was significantly higher than that in \n",
      "non-carriers (17.9% vs 3.6%; HR 7.0 95% CI 3.3–14.9; p < 0.001) . \n",
      "determine the risk of contralateral breast cancer in BRCA1 (N = 218), \n",
      "compared to BRCA1 and BRCA2 carriers. The 10 and 20-year cumulative \n",
      "(95%CI 50–99) for TP53 carriers as compared to 32% (95% CI 24–43) \n",
      "13.0–32.1) and 45% (95% CI 31.4–61.9) for BRCA2 carriers . The \n",
      "difference in 10-year cumulative risk of contralateral breast cancer in \n",
      "TP53 carriers among these two studies (i.e., 17.9% in the Chinese and \n",
      "ulations, being unselected for the first one and highly selected for the \n",
      "second one. \n",
      "\n",
      "To our knowledge, no data are available regarding survival outcomes \n",
      "of metastatic breast cancer patients according to germline TP53 muta-\n",
      "tional status. \n",
      "\n",
      "carriers are required. \n",
      "\n",
      "Among 16 Brazilian patients with breast cancer and germline TP53 p. \n",
      "R337H pathogenic variant, 12 received adjuvant radiotherapy. After a \n",
      "median follow-up exceeding 50 months, 2 (16.7%) patients developed a \n",
      "after a median follow-up of 12.5 years, 2 (11.1%) patients developed a \n",
      "and the other developed sarcoma in the radiation field . In a French \n",
      "cohort of 8 Li–Fraumeni patients with breast cancer, 6 received radio-\n",
      "therapy and 2 of them (33.3%) developed a secondary malignancy in the \n",
      "radiation field after a median follow-up of 6 years . The secondary \n",
      ". Moreover, one patient developed papillary thyroid carcinoma in-\n",
      "side the radiation field . Other smaller case-series showed similar \n",
      "results [61,75–77]. \n",
      "\n",
      "therapy should be considered with a multidisciplinary team and patient, \n",
      "with careful weighing of the risks and benefits, especially for patients \n",
      "\n",
      "Other findings \n",
      "\n",
      "Anticancer treatments \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025224\fE. Blondeaux et al. \n",
      "\n",
      "who need adjuvant radiotherapy after mastectomy . \n",
      "\n",
      "To our knowledge, no evidence is available on the safety of radiation- \n",
      "guided imaging, such as bone scintigraphy, computed tomography scans \n",
      "and positron emission tomography scans, in patients with TP53 patho-\n",
      "genic variant. \n",
      "\n",
      "made. Current guidelines recommend that radiation therapy should be \n",
      "ondary malignancies and that mastectomy rather than lumpectomy is \n",
      "have a significantly increased risk of further loco-regional disease but no \n",
      "increased risk of dying when treated with breast conserving surgery as \n",
      "compared to mastectomy, we might assume that similarly, mastectomy \n",
      "could also play a role in reducing the role of locoregional recurrences in \n",
      "population. \n",
      "\n",
      "reducing mastectomy on life expectancy is available among TP53 car-\n",
      "increasing age at surgery . Thus, due to the higher risk of contra-\n",
      "lateral breast cancer in TP53 carriers compared to BRCA1 and BRCA2 \n",
      "reducing mastectomy . However, the other cancer risks associated \n",
      "with TP53 pathogenic variants should be taken into account during the \n",
      "surgical counselling . \n",
      "\n",
      "Regarding the use of chemotherapy, Kasper and colleagues suggested \n",
      "that radiotherapy and genotoxic chemotherapies could increase the risk \n",
      "of new tumor development in a Li-Fraumeni syndrome mouse model. In \n",
      "particular, TP53 mutant mice exposed to genotoxic agent (i.e. etoposide) \n",
      "had an increased risk of tumor development, whereas the exposure to \n",
      "chemotherapy to the development of subsequent primary tumors among \n",
      "TP53 carriers derives from patients treated for childhood cancers . \n",
      "Based on these findings, the European Reference Network GENTURIS \n",
      "recommends that priority should be given to surgical or ablative treat-\n",
      "ments, avoiding radiotherapy and preferring the use of non-genotoxic \n",
      "Focusing on breast cancer treatment, despite HER2-positive tumors is \n",
      "the most frequent subtype among patients with TP53 pathogenic vari-\n",
      "ants, no data on treatment response to different chemotherapeutic and \n",
      "targeted therapy agents are available. A small study showed that TP53 \n",
      "carriers treated with carboplatin-containing neoadjuvant chemotherapy \n",
      "reached a higher rate of pathological complete response as compared to \n",
      "chemotherapy regimens . Recently, poly ADP ribose polymerase in-\n",
      "hibitors (PARPi) have been studied in patients with a pathogenic variant \n",
      "in homologous recombination genes other than BRCA. However, TP53 is \n",
      "not involved in the homologous recombination path, thus germline TP53 \n",
      "carriers were excluded from both the TBCRC-048 and the Talazoparib \n",
      "Beyond BRCA trial [85,86]. \n",
      "\n",
      "Survivorship \n",
      "\n",
      "Guidelines recommend that TP53 carriers should follow a dedicated \n",
      "cancer surveillance protocol [27,87,88]. Guidelines and recommenda-\n",
      "tions for second primary cancer surveillance among adult female TP53 \n",
      "carriers are summarized in Table 4. \n",
      "\n",
      "resonance imaging (MRI) (from age 20) for breast cancer surveillance, \n",
      "consensus on the use of mammography, only routinely recommended by \n",
      "the NCCN guidelines and by the TORONTO protocol, [80,89] or in case \n",
      "\n",
      "Table 4 \n",
      "Guidelines and recommendations for surveillance in adult female TP53 carriers. \n",
      "\n",
      "Breast cancer \n",
      "surveillance \n",
      "\n",
      "Other cancers \n",
      "surveillance \n",
      "\n",
      "- Clinical breast \n",
      "examination, every 6 \n",
      "months from age 20–25 \n",
      "or 5–10 years before the \n",
      "earliest case of breast \n",
      "cancer in the family. \n",
      "- Annual mammography \n",
      "and breast MRI from age \n",
      "to 75 or 5–10 years \n",
      "before the earliest case of \n",
      "breast cancer in the \n",
      "family- Breast US with \n",
      "mammography \n",
      "(as indicated by breast \n",
      "density) \n",
      "- Consider RRM \n",
      "\n",
      "Modified TORONTO \n",
      "\n",
      "protocol - \n",
      "American guidelines \n",
      "\n",
      "- Clinical breast \n",
      "examination every 6 \n",
      "months from age 20 \n",
      "- Annual breast MRI from \n",
      "age 20 to 75 \n",
      "- Consider RRM \n",
      "\n",
      "ESMO guidelines \n",
      "\n",
      "ESO-ESMO (BCY5) \n",
      "guidelines \n",
      "\n",
      "NCCN guidelines \n",
      "\n",
      "- Clinical breast \n",
      "examination every 6–12 \n",
      "months from age 20–25 \n",
      "- Annual breast MRI from \n",
      "age 20 to 75. If MRI is not \n",
      "available, \n",
      "mammography may be \n",
      "considered. \n",
      "- Consider RRM \n",
      "\n",
      "- Annual breast MRI and \n",
      "mammography with or \n",
      "without ultrasound \n",
      "\n",
      "- Clinical breast \n",
      "examination, every 6–12 \n",
      "months from age 20 \n",
      "- Annual breast MRI from \n",
      "age 20 to 75 \n",
      "- Mammography \n",
      "considering \n",
      "tomosynthesis from age \n",
      "- Consider RRM \n",
      "\n",
      "- Complete clinical \n",
      "examination (including \n",
      "neurologic exam) and \n",
      "blood test every 3–4 \n",
      "months \n",
      "Brain tumor \n",
      "- Annual brain MRI \n",
      "Soft tissue and bone \n",
      "sarcoma \n",
      "- Annual WBMRI \n",
      "GI tumors \n",
      "- Colonoscopy every 2 \n",
      "years from age 25 or 10 \n",
      "years before the earliest \n",
      "known colorectal cancer \n",
      "in the family \n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination \n",
      "- Complete clinical \n",
      "examination every 6 \n",
      "months \n",
      "Brain tumor \n",
      "- Annual brain MRI (only \n",
      "first MRI with \n",
      "gadolinium \n",
      "enhancement) \n",
      "Soft tissue and bone \n",
      "sarcoma \n",
      "- Annual WBMRI \n",
      "Alternated to: \n",
      "- Annual US of abdomen \n",
      "and pelvis \n",
      "GI tumors \n",
      "- Upper endoscopy and \n",
      "colonoscopy every 2–5 \n",
      "years from age 25 \n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination \n",
      "- Consider 6-monthly \n",
      "complete blood count \n",
      "Brain tumor and \n",
      "sarcoma \n",
      "- Consider annual \n",
      "\n",
      "- Annual neurological \n",
      "examination \n",
      "GI tumors \n",
      "- Colonoscopy every 5 \n",
      "years from the age of 25 \n",
      "or as clinically indicated \n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination \n",
      "- Annual brain MRI \n",
      "- Annual WBMRI \n",
      "(without Gadolinium \n",
      "enhancement) \n",
      "- Clinical exam including \n",
      "neurologic examination \n",
      "every 6–12 months \n",
      "Brain Tumor \n",
      "- Annual brain MRI \n",
      "Sarcoma \n",
      "- Annual WBMRI \n",
      "GI tumors \n",
      "- Colonoscopy and upper \n",
      "endoscopy every 2–5 \n",
      "years from age 25 or 5 \n",
      "years before the earliest \n",
      "known colon or gastric \n",
      "cancer in the family \n",
      "\n",
      "(continued on next page) \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025225\fE. Blondeaux et al. \n",
      "\n",
      "Table 4 (continued ) \n",
      "\n",
      "Table 4 (continued ) \n",
      "\n",
      "Breast cancer \n",
      "surveillance \n",
      "\n",
      "Other cancers \n",
      "surveillance \n",
      "\n",
      "Breast cancer \n",
      "surveillance \n",
      "\n",
      "Other cancers \n",
      "surveillance \n",
      "\n",
      "The European Reference \n",
      "Network GENTURIS \n",
      "guidelines \n",
      "\n",
      "- Annual breast MRI from \n",
      "age 20 to 65 \n",
      "- Consider RRM \n",
      "\n",
      "UKCGG Consensus \n",
      "\n",
      "Group guidelines \n",
      "\n",
      "- Annual breast MRI from \n",
      "age 20–70 \n",
      "\n",
      "Kumamoto et al 2021 \n",
      "\n",
      "- Breast exam twice a \n",
      "year from the age of 20 \n",
      "- Breast MRI every year \n",
      "from 20 to 75 years \n",
      "- Consider RRM \n",
      "\n",
      "Australian \n",
      "\n",
      "Recommendations \n",
      "\n",
      "- Clinical breast \n",
      "examination every 6 \n",
      "months from age 20 \n",
      "- Annual breast MRI from \n",
      "age 20 \n",
      "- Consider RRM \n",
      "\n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination from the \n",
      "age of 18 \n",
      "- Annual clinical \n",
      "examination \n",
      "Brain Tumor \n",
      "- Annual brain MRI until \n",
      "years alternated to \n",
      "WBMRI (only the first \n",
      "with gadolinium \n",
      "enhancement) \n",
      "Sarcoma \n",
      "- Annual WBMRI \n",
      "(without gadolinium \n",
      "enhancement) \n",
      "GI tumors \n",
      "- Colonoscopy every 5 \n",
      "years from age 18 (Only \n",
      "if the carrier received \n",
      "abdominal radiotherapy \n",
      "for a previous cancer or if \n",
      "there is a family history \n",
      "of colorectal tumors \n",
      "suggestive of an \n",
      "increased genetic risk) \n",
      "- Routine clinical \n",
      "examination not \n",
      "recommended \n",
      "Brain tumor \n",
      "- Annual brain MRI (only \n",
      "first MRI with \n",
      "gadolinium \n",
      "enhancement) \n",
      "Soft tissue and bone \n",
      "sarcoma \n",
      "- Annual WBMRI \n",
      "(without gadolinium \n",
      "enhancement) \n",
      "GI tumors \n",
      "- Colonoscopy only \n",
      "indicated when family \n",
      "history of colorectal \n",
      "cancer or polyposis is \n",
      "present \n",
      "- Gastric endoscopy not \n",
      "indicated \n",
      "Melanoma \n",
      "- Annual dermatology \n",
      "review \n",
      "- Clinical examination \n",
      "every 6 months \n",
      "Brain tumor \n",
      "- Annual brain MRI (only \n",
      "first with gadolinium \n",
      "enhancement) \n",
      "Soft tissue and bone \n",
      "sarcoma \n",
      "- Annual WBMRI \n",
      "alternated to: \n",
      "- Annual US of abdomen \n",
      "and pelvis \n",
      "GI tumors \n",
      "- Upper endoscopy and \n",
      "colonoscopy every 2–5 \n",
      "years from age of 25 \n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination \n",
      "Brain tumor \n",
      "- Annual brain MRI (only \n",
      "first with gadolinium \n",
      "enhancement) \n",
      "Soft tissue and bone \n",
      "sarcoma \n",
      "\n",
      "- Annual WBMRI (only \n",
      "first with gadolinium \n",
      "enhancement) \n",
      "GI tumors \n",
      "- Upper endoscopy and \n",
      "colonoscopy every 2–5 \n",
      "years from age 20–25 or \n",
      "younger dependent on \n",
      "family history \n",
      "Melanoma \n",
      "- Annual dermatological \n",
      "examination from age 18 \n",
      "\n",
      "gastrointestinal. \n",
      "\n",
      "microcalcification are not optimally detected by MRI. \n",
      "\n",
      "Considering the high risk of developing other tumors correlated with \n",
      "increased rate of gastrointestinal cancer, all guidelines agree to recom-\n",
      "mend annual whole-body MRI (generally from the age of 20) and annual \n",
      "most guidelines suggest to tailor the indication and timing according to \n",
      "the family history. Many trials are currently ongoing with the aim of \n",
      "(NCT03176836, NCT01464086, NCT02950987). \n",
      "\n",
      "In summary, according to guidelines, surveillance for breast cancer \n",
      "should be based on annual breast MRI starting at the age of 20 and risk- \n",
      "reducing surgery should be discussed with the patients (Fig. 1). For brain \n",
      "tumors and sarcoma, annual whole-body MRI should be performed since \n",
      "birth while gastrointestinal and melanoma secondary prevention should \n",
      "be considered in adulthood (Fig. 2). \n",
      "\n",
      "Regular follow up of patients with breast cancer should be scheduled \n",
      "based on current guidelines, considering not only the type of tumor, its \n",
      "biology and the treatment received, but also minimizing the diagnostic \n",
      "malignancies in these patients. Contrast-free diffusion-weighted whole- \n",
      "body MRI has proved to be effective for staging and follow-up in patients \n",
      "with breast cancer [89,93–96]. \n",
      "\n",
      "Finally, although limited evidence exist on the topic, all TP53 car-\n",
      "riers should be made aware of their risk of malignancy and the possible \n",
      "symptoms as well as encouraged to make positive lifestyle choices (e.g., \n",
      "not smoking, limit alcohol and red meat consumption, high fruits and \n",
      "lifestyle factors and health behavior among TP53 carriers suggested that \n",
      "physical activity . \n",
      "\n",
      "Other components of survivorship care in TP53 carriers should be \n",
      "only by surveillance of recurrence and second primary malignancies but \n",
      "conditions, psychological effects and its social, work and financial im-\n",
      "plications . \n",
      "\n",
      "Spectrum of TP53 alterations and testing diagnostic perspective \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025226\fE. Blondeaux et al. \n",
      "\n",
      "Fig. 1. Surveillance for breast cancer in germline TP53 female carriers. \n",
      "Dark green indicates high agreement, light green indicates medium agreement and yellow indicates very low agreement between guidelines \n",
      "Filled arrows indicate agreement on the timing of examinations recommended between guidelines \n",
      "Shaded arrows indicate discordance on the timing of examinations recommended between guidelines \n",
      "*To be considered in case the MRI could not be performed. Recommended only by NCCN guidelines and by the TORONTO protocol. Attention should be paied to \n",
      "radiation-induced malignancies. \n",
      "**as indicated by breast density \n",
      "Footnote: no universal recomendation for mammography and breast ultrasound \n",
      "\n",
      "Fig. 2. Surveillance for cancers other than breast in TP53 carriers. \n",
      "Dark green indicates high agreement, light green indicates medium agreement \n",
      "Filled arrows indicate agreement on the timing of examinations recommended between guidelines \n",
      "Shaded arrows indicate discordance on the timing of examinations recommended between guidelines \n",
      "* Annual WBMRI can be alternated to annual US of abdomen and pelvis (one radiological evaluation performed every 6 months) \n",
      "** every 2–5 years. Recommended if the carrier received abdominal radiotherapy or if there is a family history of upper GI and/or colorectal tumors \n",
      "\n",
      "Pathogenic variants are assumed to be of germline origin when the allele \n",
      "quencies (i.e., < 25–35%) might be found in a genetic report. In this \n",
      "\n",
      "derived from the mutated cell will carry the pathogenic variant . If \n",
      "the mutation is restricted to the hematopoietic compartment, it is called \n",
      "clonal hematopoiesis. Large cohort studies have demonstrated that the \n",
      "prevalence of clonal hematopoiesis increases with age and that clonal \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025227\fE. Blondeaux et al. \n",
      "\n",
      "population [100–103]. Clonal hematopoiesis has most frequently been \n",
      "reported with TP53 gene compared to other breast cancer susceptibility \n",
      "pathogenic variant the possibility of mosaicism should be ruled out as in \n",
      "this case different therapeutic and genetic counselling needs are impli-\n",
      "cated . \n",
      "\n",
      "Identification of a TP53 pathogenic variant does not always translate \n",
      "into the diagnosis of Li-Fraumeni syndrome. The different pathogenic \n",
      "variants can have different penetrance and thus different phenotypes. A \n",
      "older age of occurrence of cancers of the Li-Fraumeni syndrome spec-\n",
      "trum. For example, the funder mutation p.R181C in the TP53 gene was \n",
      "found among 9 out of 453 Palestinian young women with breast cancer. \n",
      "None of the families that harbored the TP53 p.R181C likely pathogenic \n",
      "Similarly, the penetrance of the p.R337H TP53 pathogenic variant seem \n",
      "to be incomplete. In Southern Brazil, the population prevalence of TP53 \n",
      "p.R337H pathogenic variant is 0.3%. In the Brazilian population, this \n",
      "variant seems to be associated with adrenocortical tumors in children \n",
      "[105–107]. \n",
      "\n",
      "Understanding the factors that lead to phenotypic differences among \n",
      "TP53 carries is important to tailor the surveillance program and coun-\n",
      "Kratz and colleagues seem to be a valid approach to classify the different \n",
      "phenotypic spectrums of TP53 variants . Authors classified germ-\n",
      "line TP53 variants of 3034 persons into: phenotypic Li-Fraumeni syn-\n",
      "drome (i.e., absence of a pathogenic/likely pathogenic TP53 variant in \n",
      "attenuated Li-Fraumeni syndrome (i.e., presence of a pathogenic/likely \n",
      "pathogenic TP53 variant in a person with cancer who does not meet Li- \n",
      "Fraumeni syndrome testing criteria), incidental Li-Fraumeni syndrome \n",
      "(i.e, presence of a pathogenic/likely pathogenic TP53 variant in a person \n",
      "without a history of cancer). Results showed that patients who met Li- \n",
      "Fraumeni syndrome genetic testing criteria have more frequently early \n",
      "adrenal, brain, connective tissue, or bone tumors. While carriers who did \n",
      "not meet Li-Fraumeni syndrome genetic testing criteria had more breast \n",
      "and other cancers (45% of them occurring after age 45 years) . \n",
      "\n",
      "cancer individual triggers cascade genetic testing of relatives (including \n",
      "vention. As the information regarding the identification of a pathogenic \n",
      "variant in the family relies in proband (proband-mediated procedure), it \n",
      "is uncertain whether all eligible relatives access testing. To our knowl-\n",
      "members are available. Moreover, testing of asymptomatic children at \n",
      "risk of Li Fraumeni syndrome remained controversial for a long time, \n",
      "due to the lack of proven medical benefit of screening, concern about \n",
      "wards the minor . However, due to emerging screening protocols \n",
      "showing potential efficacy, testing of at-risk children is becoming more \n",
      "available [89,94]. Nevertheless, future research should also focus on the \n",
      "long-term clinical and psychosocial impacts of TP53 genetic testing and \n",
      "early detection of such pathogenic variants in minors. \n",
      "\n",
      "offspring. Thus, current guidelines recommend that TP53 carriers should \n",
      "\n",
      "burden of additional psychological distress . To our knowledge, no \n",
      "information is available regarding awareness, acceptance, and uptake of \n",
      "carriers. \n",
      "\n",
      "Conclusions \n",
      "\n",
      "germline pathogenic variants in TP53 ranges from <0.5% in unselected \n",
      "patients with breast cancer to around 5–10% in highly selected patients \n",
      "with breast cancer such as those with very young age at diagnosis or \n",
      "guidelines recommend that radiotherapy should be avoided and mas-\n",
      "tectomy should be preferred to lumpectomy [27,78,79]. Moreover, risk- \n",
      "[27,78,79]. Whole-body MRI should be used for secondary cancer sur-\n",
      "veillance. No information is available regarding potential differences in \n",
      "symptoms suggesting the occurrence of these events. \n",
      "\n",
      "The identification of a TP53 pathogenic variant is not a straightfor-\n",
      "ward to the diagnosis of Li-Fraumeni syndrome as different penetrance \n",
      "and phenotypes are present. No information on the uptake of cascade \n",
      "exist on the implication of genetic testing in minors. Current guidelines \n",
      "should be offered to patients willing to conceive [110,111]. Finally, the \n",
      "identification of a minor allele frequency of pathogenic variant needs \n",
      "affect both cascade testing and preimplantation and prenatal testing. \n",
      "\n",
      "Considering the limited data available to counsel patients with breast \n",
      "cancer and germline TP53 pathogenic variants, the low level of evidence \n",
      "on some of the topic presented, the relatively rarity of this condition, and \n",
      "clonal hematopoiesis and mosaicism), collaborative research efforts are \n",
      "strongly encouraged in order to provide more solid answers to improve \n",
      "and better tailor the care of this special patient population. \n",
      "\n",
      "CRediT authorship contribution statement \n",
      "\n",
      "Eva Blondeaux: Conceptualization, Writing – original draft, Writing \n",
      "– review & editing, Funding acquisition. Luca Arecco: Writing – review \n",
      "Visualization, Supervision. Rossella Graffeo: Writing – review & edit-\n",
      "ing, Visualization, Supervision. Angela Toss: Writing – review & edit-\n",
      "ing, Visualization, Supervision. Carmine De Angelis: Writing – review \n",
      "& editing, Visualization, Supervision. Lucia Trevisan: Writing – review \n",
      "Visualization. Sabine C. Linn: Writing – review & editing, Visualization, \n",
      "Supervision. Peter Dubsky: Writing – review & editing, Visualization, \n",
      "Supervision. Mara Cruellas: Writing – review & editing, Visualization. \n",
      "Ann H. Partridge: Writing – review & editing, Visualization, Supervi-\n",
      "Supervision. \n",
      "\n",
      "Declaration of Competing Interest \n",
      "\n",
      "lationships which may be considered as potential competing interests: \n",
      "‘Eva Blondeaux reports research grant (to the Institution) from Gilead \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025228\fE. Blondeaux et al. \n",
      "\n",
      "to pursue research effort in the field of TP53 pathogenic variants. Kevin \n",
      "Zeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead Sciences, MSD, \n",
      "roles paid to my institution from Astra Zeneca, Eli Lilly, Exact Sciences, \n",
      "Gilead, MSD, Novartis, Pfizer, Roche, Seagen. Research funding paid to \n",
      "De Angelis reports advisory role for Roche, Lilly, Novartis, Astrazeneca, \n",
      "Lilly, Novartis, Pfizer, Seagen, and GSK, Travel Grants from Gilead and \n",
      "research support (to the Institution) from Novartis outside the submitted \n",
      "Daiichi Sankyo Europe GmbH (paid to the institution), travel and ac-\n",
      "neca, Bristol Myers Squibb, Tesaro (now GSK), Merck, Immunomedics \n",
      "(now Gilead), Eurocept Pharmaceuticals, Agendia, and Novartis. Mara \n",
      "Cruellas reports speaker honoraria from Roche and Astrazeneca. Shani \n",
      "Paluch-Shimon reports - advisory Board consultancy, speaker’s bureau: \n",
      "AstraZeneca, Pfizer, Novartis, Lilly, Roche, MSD, Exact Sciences. Gilead. \n",
      "Lilly, Novartis, Pfizer, Sandoz, Libbs, Daiichi Sankyo and Takeda, Travel \n",
      "Grants from Gilead and research support (to the Institution) from Gilead \n",
      "outside the submitted work. All the other authors declare no conflict of \n",
      "interest.’ \n",
      "\n",
      "Acknowledgment \n",
      "\n",
      "Medical Grant (Fellowship Program 2022) (no grant number). \n",
      "\n",
      "writing of the manuscript; and in the decision to submit the article for \n",
      "publication \n",
      "\n",
      "References \n",
      "\n",
      " Rosenberg SM, Newman LA, Partridge AH. Breast cancer in young women: rare \n",
      "\n",
      "disease or public health problem? JAMA Oncol 2015;1(7):877–8. \n",
      "\n",
      " Euhus DM. Understanding mathematical models for breast cancer risk assessment \n",
      "\n",
      "and counseling. Breast J 2001;7(4):224–32. \n",
      "\n",
      " Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of \n",
      "germline mutations in 25 cancer susceptibility genes in a sequential series of \n",
      "patients with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2016;34(13): \n",
      "1460–8. \n",
      "\n",
      " Pharoah PDP, Dunning AM, Ponder BAJ, Easton DF. Association studies for \n",
      "\n",
      "finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4(11): \n",
      "850–60. \n",
      "\n",
      " Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, Gonz´alez- \n",
      "Neira A, Luccarini C, et al. Breast Cancer Risk Genes — Association Analysis in \n",
      "More than 113,000 Women. N Engl J Med. 2021;384(5):428–39. \n",
      "\n",
      " Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based \n",
      "study of genes previously implicated in breast cancer. N Engl J Med 2021;384(5): \n",
      "440–51. \n",
      "\n",
      " Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, \n",
      "consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2(1): \n",
      "a001008. \n",
      "\n",
      " Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, et al. Prevalence and clinical impact \n",
      "of TP53 germline mutations in Chinese women with breast cancer. Int J Cancer \n",
      "2020;146(2):487–95. \n",
      "\n",
      " Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A \n",
      "\n",
      "familial syndrome? Ann Intern Med 1969;71(4):747–52. \n",
      "\n",
      " Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez- \n",
      "\n",
      "Galindo C, Zambetti GP, et al. Prevalence and functional consequence of TP53 \n",
      "mutations in pediatric adrenocortical carcinoma: a children’s oncology group \n",
      "study. J Clin Oncol Off J Am Soc Clin Oncol 2015;33(6):602–9. \n",
      "\n",
      " Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline \n",
      "\n",
      "mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;373 \n",
      "(24):2336–46. \n",
      "\n",
      " Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in \n",
      "germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr \n",
      "Opin Oncol 2018;30(1):23–9. \n",
      "\n",
      " Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, et al. \n",
      "\n",
      "Inherited TP53 variants and risk of prostate cancer. Eur Urol 2022;81(3):243–50. \n",
      " Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis \n",
      "of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet \n",
      "1992;51(2):344–56. \n",
      "\n",
      " Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and \n",
      "sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006;66(16):8287–92. \n",
      " Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of \n",
      "the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline \n",
      "mutation carriers. Hum Genet 2011;130(6):789–94. \n",
      "\n",
      " Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort \n",
      "\n",
      "with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72 \n",
      "(4):975–83. \n",
      "\n",
      " Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation \n",
      "and new primary tumours after therapeutic radiation for benign disease: \n",
      "substantial risks in certain tumour prone syndromes. J Med Genet 2006;43(4): \n",
      "289–94. \n",
      "\n",
      " Schon K, Tischkowitz M. Clinical implications of germline mutations in breast \n",
      "\n",
      "cancer: TP53. Breast Cancer Res Treat 2018;167(2):417–23. \n",
      "\n",
      " Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, \n",
      "\n",
      "et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and \n",
      "BRCA2 mutation carriers. JAMA 2017;317(23):2402. \n",
      "\n",
      " Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first \n",
      "\n",
      "and subsequent cancers among TP53 mutation carriers in the National Cancer \n",
      "Institute Li-Fraumeni syndrome cohort. Cancer 2016;122(23):3673–81. \n",
      " Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. \n",
      "\n",
      "A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48(18): \n",
      "5358–62. \n",
      "\n",
      " Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. \n",
      "\n",
      "Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li- \n",
      "Fraumeni families. Cancer Res 1994;54(5):1298–304. \n",
      "\n",
      " Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995;25:101–24. \n",
      " Chompret A, Abel A, Stoppa-Lyonnet D, Brugi´eres L, Pag´es S, Feunteun J, et al. \n",
      "Sensitivity and predictive value of criteria for p53 germline mutation screening. \n",
      "J Med Genet 2001;38(1):43–7. \n",
      "\n",
      " Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, \n",
      "et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol \n",
      "Off J Am Soc Clin Oncol 2015;33(21):2345–52. \n",
      "\n",
      " Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, \n",
      "\n",
      "Network ER, et al. Guidelines for the Li-Fraumeni and heritable TP53-related \n",
      "cancer syndromes. Eur J Hum Genet EJHG 2020;28(10):1379–86. \n",
      " Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T. \n",
      "\n",
      "Germline TP53 testing in breast cancers: why, when and how? Cancers 2020;12 \n",
      "(12):E3762. \n",
      "\n",
      " Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. \n",
      "version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol Off \n",
      "J Am Soc Clin Oncol. 2009;27(26):e108–109; author reply e110. \n",
      "\n",
      " Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. \n",
      "\n",
      "Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 \n",
      "germline mutations. J Clin Oncol Off J Am Soc Clin Oncol 2009;27(8):1250–6. \n",
      " Ruijs MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FBL, \n",
      "\n",
      "et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni \n",
      "syndrome: mutation detection rate and relative frequency of cancers in different \n",
      "familial phenotypes. J Med Genet 2010;47(6):421–8. \n",
      "\n",
      " Renaux-Petel M, Charbonnier F, Th´ery JC, Fermey P, Lienard G, Bou J, et al. \n",
      "\n",
      "Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. \n",
      "J Med Genet 2018;55(3):173–80. \n",
      "\n",
      " Bakhuizen JJ, Hogervorst FB, Velthuizen ME, Ruijs MW, van Engelen K, van \n",
      "\n",
      "Os TA, et al. TP53 germline mutation testing in early-onset breast cancer: findings \n",
      "from a nationwide cohort. Fam Cancer 2019;18(2):273–80. \n",
      "\n",
      " Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen \n",
      "J, Gonz´alez-Neira A, et al. Pathology of Tumors Associated With Pathogenic \n",
      "Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. 2022;8 \n",
      "(3):e216744. \n",
      "\n",
      " Evans DGR, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM. Low rate \n",
      "of TP53 germline mutations in breast cancer/sarcoma families not fulfilling \n",
      "classical criteria for Li-Fraumeni syndrome. J Med Genet 2002;39(12):941–4. \n",
      "\n",
      " Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of \n",
      "mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast \n",
      "cancer. JAMA 2006;295(12):1379–88. \n",
      "\n",
      " Lalloo F, Varley J, Moran A, Ellis D, O’dair L, Pharoah P, et al. BRCA1, BRCA2 \n",
      "\n",
      "and TP53 mutations in very early-onset breast cancer with associated risks to \n",
      "relatives. Eur J Cancer Oxf Engl 1990. 2006;42(8):1143–50. \n",
      "\n",
      " Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, et al. \n",
      "\n",
      "Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. \n",
      "Eur J Cancer Oxf Engl 2007;43(3):601–6. \n",
      "\n",
      " Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, et al. The \n",
      "\n",
      "prevalence of germ-line TP53 mutations in women diagnosed with breast cancer \n",
      "before age 30. Fam Cancer 2009;8(4):563–7. \n",
      "\n",
      " Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MRE, et al. Population- \n",
      "based estimate of the contribution of TP53 mutations to subgroups of early-onset \n",
      "breast cancer: Australian Breast Cancer Family Study. Cancer Res 2010;70(12): \n",
      "4795–800. \n",
      "\n",
      "CancerTreatmentReviews114(2023)1025229\fE. Blondeaux et al. \n",
      "\n",
      " Lee DSC, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, et al. Comparable \n",
      "\n",
      "frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic \n",
      "Asian cohort suggests TP53 screening should be offered together with BRCA1/2 \n",
      "screening to early-onset breast cancer patients. Breast Cancer Res BCR 2012;14 \n",
      "(2):R66. \n",
      "\n",
      " McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, et al. \n",
      "Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam \n",
      "Cancer 2012;11(4):607–13. \n",
      "\n",
      " Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, et al. Prevalence of \n",
      "\n",
      "germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res \n",
      "Treat 2013;139(1):193–8. \n",
      "\n",
      " Carraro DM, Koike Folgueira MAA, Garcia Lisboa BC, Ribeiro Olivieri EH, \n",
      "\n",
      "Vitorino Krepischi AC, de Carvalho AF, et al. Comprehensive analysis of BRCA1, \n",
      "BRCA2 and TP53 germline mutation and tumor characterization: a portrait of \n",
      "early-onset breast cancer in Brazil. PLoS One 2013;8(3):e57581. \n",
      "\n",
      " Eccles DM, Li N, Handwerker R, Maishman T, Copson ER, Durcan LT, et al. \n",
      "\n",
      "Genetic testing in a cohort of young patients with HER2-amplified breast cancer. \n",
      "Ann Oncol Off J Eur Soc Med Oncol 2016;27(3):467–73. \n",
      "\n",
      " Hahn EC, Bittar CM, Vianna FSL, Netto CBO, Biazús JV, Cericatto R, et al. TP53 p. \n",
      "Arg337His germline mutation prevalence in Southern Brazil: further evidence for \n",
      "mutation testing in young breast cancer patients. PloS One 2018;13(12): \n",
      "e0209934. \n",
      "\n",
      " Gallardo-Alvarado LN, Tusi´e-Luna MT, Tussi´e-Luna MI, Díaz-Ch´avez J, \n",
      "\n",
      "Segura YX, Bargallo-Rocha E, et al. Prevalence of germline mutations in the TP53 \n",
      "gene in patients with early-onset breast cancer in the Mexican population. BMC \n",
      "Cancer 2019;19(1):118. \n",
      "\n",
      " Rogo ˙za-Janiszewska E, Mali´nska K, G´orski B, Scott RJ, Cybulski C, Klu´zniak W, \n",
      "et al. Prevalence of germline TP53 variants among early-onset breast cancer \n",
      "patients from Polish population. Breast Cancer Tokyo Jpn 2021;28(1):226–35. \n",
      "\n",
      " Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Iqbal K, Azam S, et al. Prevalence of \n",
      "germline TP53 mutation among early onset middle eastern breast cancer patients. \n",
      "Hered Cancer Clin Pract 2021;19(1):49. \n",
      "\n",
      " Waks AG, Kim D, Jain E, Snow C, Kirkner GJ, Rosenberg SM, et al. Somatic and \n",
      "germline genomic alterations in very young women with breast cancer. Clin \n",
      "Cancer Res Off J Am Assoc Cancer Res 2022;28(11):2339–48. \n",
      "\n",
      " Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, \n",
      "et al. Germline TP53 mutational spectrum in French Canadians with breast \n",
      "cancer. BMC Med Genet 2015;12(16):24. \n",
      "\n",
      " Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, et al. \n",
      "\n",
      "Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French \n",
      "Canadian breast cancer families. Breast Cancer Res Treat 2008;108(3):399–408. \n",
      "\n",
      " Lalloo F, Varley J, Ellis D, Moran A, O’Dair L, Pharoah P, et al. Prediction of \n",
      "\n",
      "pathogenic mutations in patients with early-onset breast cancer by family history. \n",
      "Lancet Lond Engl 2003;361(9363):1101–2. \n",
      "\n",
      " Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. \n",
      "Differences in TP53 mutation carrier phenotypes emerge from panel-based \n",
      "testing. J Natl Cancer Inst 2018;110(8):863–70. \n",
      "\n",
      " Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline \n",
      "\n",
      "variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat \n",
      "2018;39(12):1764–73. \n",
      "\n",
      " Wilson JRF, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel \n",
      "HER2-positive breast cancer phenotype arising from germline TP53 mutations. \n",
      "J Med Genet 2010;47(11):771–4. \n",
      "\n",
      " Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez- \n",
      "\n",
      "Barrera AM, et al. Early onset HER2-positive breast cancer is associated with \n",
      "germline TP53 mutations. Cancer 2012;118(4):908–13. \n",
      "\n",
      " Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, et al. Breast \n",
      "cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni \n",
      "syndrome consortium effort. Breast Cancer Res Treat 2012 Jun;133(3):1125–30. \n",
      " Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, et al. \n",
      "\n",
      "Breast cancer in patients with germline TP53 pathogenic variants have typical \n",
      "tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer \n",
      "(COPE study). J Pathol Clin Res 2019;5(3):189–98. \n",
      "\n",
      " Le AN, Harton J, Desai H, Powers J, Zelley K, Bradbury AR, et al. Frequency of \n",
      "radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in \n",
      "patients with Li-Fraumeni syndrome. Breast Cancer Res Treat 2020;181(1): \n",
      "181–8. \n",
      "\n",
      " Alyami H, Yoo TK, Cheun JH, Lee HB, Jung SM, Ryu JM, et al. Clinical features of \n",
      "breast cancer in South Korean patients with germline TP53 gene mutations. \n",
      "J Breast Cancer 2021;24(2):175–82. \n",
      "\n",
      " Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, et al. \n",
      "\n",
      "Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod Pathol \n",
      "Off J U S Can Acad Pathol Inc. 2021;34(3):542–8. \n",
      "\n",
      " Rippinger N, Fischer C, Sinn HP, Dikow N, Sutter C, Rhiem K, et al. Breast cancer \n",
      "characteristics and surgery among women with Li-Fraumeni syndrome in \n",
      "Germany-A retrospective cohort study. Cancer Med 2021;10(21):7747–58. \n",
      " Sandoval RL, Polidorio N, Leite ACR, Cartaxo M, Pisani JP, Quirino CV, et al. \n",
      "\n",
      "Breast cancer phenotype associated with Li-Fraumeni syndrome: a brazilian \n",
      "cohort enriched by TP53 p.R337H carriers. Front Oncol. 2022;12:836937. \n",
      " Sj¨ogren S, Ingan¨as M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive \n",
      "value of c-erbB-2 overexpression in primary breast cancer, alone and in \n",
      "combination with other prognostic markers. J Clin Oncol Off J Am Soc Clin Oncol \n",
      "1998;16(2):462–9. \n",
      "\n",
      " Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US \n",
      "\n",
      "incidence of breast cancer subtypes defined by joint hormone receptor and HER2 \n",
      "status. J Natl Cancer Inst. 2014;106(5):dju055. \n",
      "\n",
      " Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IRK, Ikdahl T, et al. TP53 \n",
      "mutation status and gene expression profiles are powerful prognostic markers of \n",
      "breast cancer. Breast Cancer Res BCR 2007;9(3):R30. \n",
      "\n",
      " Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast \n",
      "cancer: reading beyond the headlines. Trends Cancer 2020;6(2):98–110. \n",
      " Eikesdal HP, Knappskog S, Aas T, Lønning PE. TP53 status predicts long-term \n",
      "survival in locally advanced breast cancer after primary chemotherapy. Acta \n",
      "Oncol Stockh Swed 2014;53(10):1347–55. \n",
      "\n",
      " Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Ingan¨as M, et al. Worse \n",
      "survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. \n",
      "Ann Oncol Off J Eur Soc Med Oncol 2005;16(5):743–8. \n",
      "\n",
      " Guo Y, Wan Q, Ouyang T, Li J, Wang T, Fan Z, et al. Risk of ipsilateral breast \n",
      "tumor recurrence and contralateral breast cancer in patients with and without \n",
      "TP53 variant in a large series of breast cancer patients. Breast 2022;1(65):55–60. \n",
      " Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, et al. \n",
      "Risk of contralateral breast cancer in women with and without pathogenic \n",
      "variants in BRCA1, BRCA2, and TP53 genes in women with very early-onset (<36 \n",
      "years) breast cancer. Cancers 2020;12(2):E378. \n",
      "\n",
      " Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos R do NG, Cotti GC, et al. \n",
      "\n",
      "Radiotherapy-induced malignancies in breast cancer patients with TP53 \n",
      "pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer 2020;19(1): \n",
      "47–53. \n",
      "\n",
      " Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio- \n",
      "induced malignancies after breast cancer postoperative radiotherapy in patients \n",
      "with Li-Fraumeni syndrome. Radiat Oncol Lond Engl 2010;8(5):104. \n",
      " Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li- \n",
      "\n",
      "Fraumeni syndrome - a case-series study and review of literature. Breast Cancer \n",
      "Dove Med Press 2017;9:207–15. \n",
      "\n",
      " Kappel S, Janschek E, Wolf B, Rudas M, Teleky B, Jakesz R, et al. TP53 germline \n",
      "mutation may affect response to anticancer treatments: analysis of an intensively \n",
      "treated Li-Fraumeni family. Breast Cancer Res Treat 2015;151(3):671–8. \n",
      " Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, et al. \n",
      "Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical \n",
      "tumors. Am J Hum Genet 1999;65(4):995–1006. \n",
      "\n",
      " Sessa C, Balma˜na J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk \n",
      "reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: \n",
      "ESMO Clinical Practice Guideline. Ann Oncol 2022. S092375342204193X. \n",
      " Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. \n",
      "\n",
      "Management of hereditary breast cancer: American Society of Clinical Oncology, \n",
      "American Society for Radiation Oncology, and Society of Surgical Oncology \n",
      "Guideline. J Clin Oncol Off J Am Soc Clin Oncol 2020;38(18):2080–106. \n",
      " Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/ \n",
      "\n",
      "familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, \n",
      "NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN \n",
      "2021;19(1):77–102. \n",
      "\n",
      " Davey MG, Davey CM, Ryan ´EJ, Lowery AJ, Kerin MJ. Combined breast \n",
      "conservation therapy versus mastectomy for BRCA mutation carriers – A \n",
      "systematic review and meta-analysis. Breast 2021;56:26–34. \n",
      "\n",
      " Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on \n",
      "breast cancer incidence and mortality in BRCA mutation carriers, by age at \n",
      "mastectomy. Breast Cancer Res Treat 2018;167(1):263–7. \n",
      "\n",
      " Kasper E, Angot E, Colasse E, Nicol L, Sabourin JC, Adriouch S, et al. Contribution \n",
      "of genotoxic anticancer treatments to the development of multiple primary \n",
      "tumours in the context of germline TP53 mutations. Eur J Cancer Oxf Engl 2018; \n",
      "1990(101):254–62. \n",
      "\n",
      " Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den BE, van den Heuvel- \n",
      "Eibrink MM, van der Pal HJ, et al. Long-term risk of subsequent malignant \n",
      "neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: \n",
      "role of chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 2017;35(20): \n",
      "2288–98. \n",
      "\n",
      " Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, et al. A phase II \n",
      "study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 \n",
      "with a mutation in other homologous recombination genes. Nat Cancer 2022;3 \n",
      "(10):1181–91. \n",
      "\n",
      " Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. \n",
      "TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and \n",
      "Mutations in Homologous Recombination-Related Genes. J Clin Oncol [Internet]. \n",
      "Oct 29 [cited 2022 Oct 26]; Available from: https://ascopubs.org/doi/pdf/ \n",
      "10.1200/JCO.20.02151?role=tab. \n",
      "\n",
      " Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al. \n",
      "\n",
      "Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol \n",
      "2021;26(12):2161–78. \n",
      "\n",
      " Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, et al. UKCGG \n",
      "Consensus Group guidelines for the management of patients with constitutional \n",
      "TP53 pathogenic variants. J Med Genet. 2020;jmedgenet-2020-106876. \n",
      "\n",
      " Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. \n",
      "\n",
      "Biochemical and imaging surveillance in germline TP53 mutation carriers with \n",
      "Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. \n",
      "Lancet Oncol 2016;17(9):1295–305. \n",
      "\n",
      " Kratz CP, Achatz MI, Brugi`eres L, Frebourg T, Garber JE, Greer MLC, et al. Cancer \n",
      "screening recommendations for individuals with Li-Fraumeni syndrome. Clin \n",
      "Cancer Res Off J Am Assoc Cancer Res 2017;23(11):e38–45. \n",
      "\n",
      " Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi- \n",
      "Micheli G, et al. ESO-ESMO 5th international consensus guidelines for breast \n",
      "cancer in young women (BCY5). Ann Oncol Off J Eur Soc Med Oncol. 2022; \n",
      "S0923-7534(22)01858-0. \n",
      "\n",
      "CancerTreatmentReviews114(2023)10252210\fE. Blondeaux et al. \n",
      "\n",
      " 749-TP53 (Li-Fraumeni) – risk management (adult) | eviQ [Internet]. [cited 2022 \n",
      "Dec 5]. Available from: https://www.eviq.org.au/cancer-genetics/adult/risk- \n",
      "management/749-tp53-li-fraumeni-risk-management-adult. \n",
      "\n",
      " Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, et al. Baseline \n",
      "\n",
      "results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 \n",
      "mutation carriers and matched controls. Fam Cancer 2017;16(3):433–40. \n",
      " Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline \n",
      "surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance \n",
      "imaging: a meta-analysis. JAMA Oncol 2017;3(12):1634–9. \n",
      "\n",
      " Petralia G, Padhani AR. Whole-body magnetic resonance imaging in oncology: \n",
      "\n",
      "uses and indications. Magn Reson Imaging Clin N Am 2018;26(4):495–507. \n",
      " Omran M, Blomqvist L, Brandberg Y, Pal N, Kogner P, Ståhlbom AK, et al. Whole- \n",
      "\n",
      "body MRI within a surveillance program for carriers with clinically actionable \n",
      "germline TP53 variants - the Swedish constitutional TP53 study SWEP53. Hered \n",
      "Cancer Clin Pract 2020;13(18):1. \n",
      "\n",
      " Nees J, Kiermeier S, Struewe F, Keymling M, Maatouk I, Kratz CP, et al. Health \n",
      "behavior and cancer prevention among adults with Li-Fraumeni syndrome and \n",
      "relatives in Germany-A cohort description. Curr Oncol Tor Ont 2022;29(10): \n",
      "7768–78. \n",
      "\n",
      " Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, \n",
      "\n",
      "et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting \n",
      "high-quality survivorship care and research in Europe. Ann Oncol [Internet]. \n",
      "[cited 2022 Oct 25];0(0). Available from: https://www.annalsofoncology. \n",
      "org/article/S0923-7534(22)03792-9/fulltext. \n",
      "\n",
      " Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related \n",
      "\n",
      "mutations associated with clonal hematopoietic expansion and malignancies. Nat \n",
      "Med 2014;20(12):1472–8. \n",
      "\n",
      " Genovese G, K¨ahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. \n",
      "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. \n",
      "N Engl J Med 2014;371(26):2477–87. \n",
      "\n",
      " Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T, et al. \n",
      "Genomic analysis of inherited breast cancer among Palestinian women: Genetic \n",
      "heterogeneity and a founder mutation in TP53. Int J Cancer 2017;141(4):750–6. \n",
      "\n",
      " Giacomazzi J, Graudenz MS, Osorio CABT, Koehler-Santos P, Palmero EI, \n",
      "\n",
      "Zagonel-Oliveira M, et al. Prevalence of the TP53 p.R337H mutation in breast \n",
      "cancer patients in Brazil. PloS One 2014;9(6):e99893. \n",
      "\n",
      " Cust´odio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, et al. \n",
      "Impact of neonatal screening and surveillance for the TP53 R337H mutation on \n",
      "early detection of childhood adrenocortical tumors. J Clin Oncol Off J Am Soc \n",
      "Clin Oncol 2013;31(20):2619–26. \n",
      "\n",
      " Sandoval RL, Masotti C, de Macedo MP, Ribeiro MFSA, Leite ACR, Meireles SI, \n",
      "et al. Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling \n",
      "Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. \n",
      "JCO Glob Oncol. 2021;7:GO.21.00097. \n",
      "\n",
      " Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, et al. \n",
      "Analysis of the Li-Fraumeni spectrum based on an international germline TP53 \n",
      "variant data set: an international agency for research on cancer TP53 database \n",
      "analysis. JAMA Oncol 2021;7(12):1800–5. \n",
      "\n",
      " Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, et al. Li- \n",
      "\n",
      " Evans DG, Lunt P, Clancy T, Eeles R. Childhood predictive genetic testing for Li- \n",
      "\n",
      "Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation \n",
      "of pathogenic variants of low allele frequency and the differences between \n",
      "germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res BCR 2019; \n",
      "21(1):107. \n",
      "\n",
      "Fraumeni syndrome. Fam Cancer 2010;9(1):65–9. \n",
      "\n",
      " Vukovi´c P, Peccatori FA, Massarotti C, Miralles MS, Beketi´c-Oreˇskovi´c L, \n",
      "\n",
      "Lambertini M. Preimplantation genetic testing for carriers of BRCA1/2 \n",
      "pathogenic variants. Crit Rev Oncol Hematol 2021;157:103201. \n",
      "\n",
      " Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, et al. \n",
      "Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet \n",
      "2012;44(6):651–8. \n",
      "\n",
      " Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age- \n",
      "\n",
      "related clonal hematopoiesis associated with adverse outcomes. N Engl J Med \n",
      "2014;371(26):2488–98. \n",
      "\n",
      " Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. \n",
      "Prevention and screening in BRCA mutation carriers and other breast/ovarian \n",
      "hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer \n",
      "prevention and screening. Ann Oncol Off J Eur Soc Med Oncol 2016;27(suppl 5): \n",
      "v103–10. \n",
      "\n",
      "CancerTreatmentReviews114(2023)10252211\n"
     ]
    }
   ],
   "source": [
    "for file in os.listdir(breast_cancer_dir):\n",
    "    raw_text = read_pdf2(os.path.join(breast_cancer_dir, file))\n",
    "    # print(raw_text)\n",
    "    cleaned_text = clean_text(raw_text)\n",
    "    print(cleaned_text)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "a3a9d766",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_22153/3140654592.py:3: DeprecationWarning: `recreate_collection` method is deprecated and will be removed in the future. Use `collection_exists` to check collection existence and `create_collection` instead.\n",
      "  client.recreate_collection(\n"
     ]
    }
   ],
   "source": [
    "# Create collection\n",
    "collection_name = \"demo_collection\"\n",
    "client.recreate_collection(\n",
    "    collection_name=collection_name,\n",
    "    vectors_config=VectorParams(size=384, distance=\"Cosine\")\n",
    ")\n",
    "\n",
    "# Load model\n",
    "model = SentenceTransformer(\"sentence-transformers/all-MiniLM-L6-v2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "508cbd5d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Sample data\n",
    "texts = [\n",
    "    \"Machine learning enables computers to learn from data.\",\n",
    "    \"Vector databases store high-dimensional embeddings efficiently.\",\n",
    "    \"Qdrant makes it easy to perform semantic search.\"\n",
    "]\n",
    "\n",
    "# Generate embeddings\n",
    "embeddings = model.encode(texts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "90c84aed",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "UpdateResult(operation_id=0, status=<UpdateStatus.COMPLETED: 'completed'>)"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Insert points\n",
    "points = [\n",
    "    PointStruct(id=i, vector=embeddings[i].tolist(), payload={\"text\": texts[i]})\n",
    "    for i in range(len(texts))\n",
    "]\n",
    "client.upsert(collection_name=collection_name, points=points)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "34bde3b9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'text': 'Machine learning enables computers to learn from data.'}\n",
      "{'text': 'Vector databases store high-dimensional embeddings efficiently.'}\n",
      "{'text': 'Qdrant makes it easy to perform semantic search.'}\n"
     ]
    }
   ],
   "source": [
    "# Verify\n",
    "result = client.scroll(collection_name=collection_name, limit=3)\n",
    "for point in result[0]:\n",
    "    print(point.payload)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "412f000c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "rag_dev",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
